IRVINE, Calif., January 24, 2008 – Teva Health Systems is pleased to announce the introduction and availability of Oxytocin Injection, USP (Synthetic). This product is AP Rated* and available in 10 Units/mL, 10 Units in Single Dose Glass Vials, and 10 Units/mL, 100 Units in Multiple Dose Glass Vials.
“Our generic injectable and unit-dose pharmaceuticals are an economical choice for our health system customers,” states Jonathan Zalk, Director of Marketing. “We continue to add new products to meet the growing demand for quality, affordable alternatives to brand pharmaceuticals.”
Teva Health Systems is a part of Teva Pharmaceuticals, the leading pharmaceutical manufacturer for both new and total prescriptions.‡ The company has an aggressive Research and Development effort and one of the best overall ANDA approval records in the industry.
No comments:
Post a Comment